Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Myeloid 1Head & Neck 1Gastrointestinal 1CNS 1

Conditions

Colorectal Neoplasms 84Squamous Cell Carcinoma of Head and Neck 53Carcinoma, Non-Small-Cell Lung 30Head and Neck Neoplasms 29Colonic Neoplasms 23Neoplasm Metastasis 18Neoplasms 16Rectal Neoplasms 15Pancreatic Neoplasms 10Lung Neoplasms 10Mouth Neoplasms 8Carcinoma, Squamous Cell 8Laryngeal Neoplasms 7Hypopharyngeal Neoplasms 7Oropharyngeal Neoplasms 6Carcinoma 6Solid Tumors 5Parkinson Disease 4, Autosomal Dominant Lewy Body 5Gastrointestinal Neoplasms 5Breast Neoplasms 5Tongue Neoplasms 4Ovarian Neoplasms 4Endometrial Neoplasms 4Thyroid Neoplasms 3Recurrence 3Melanoma 3Digestive System Neoplasms 3Colorectal Cancer Metastatic 3Carcinoma, Renal Cell 3Carcinoma, Pancreatic Ductal 3

Interventions

Panitumumab 1IFL protocol 1Gemcitabine 1Cetuximab 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Histiocytosis × Cetuximab × 1 year × Clear all
NCT05786924 2026-04-21

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

Servier

Phase 1/2 Recruiting
554 enrolled
CNSGastrointestinalHead & NeckMyeloidThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms, Histiocytosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡